Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + Nivolumab in Chinese patients with advanced solid tumors
NCT05134948Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2021
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab + relatlimab in solid tumor (advanced stage), sponsored by Bristol Myers Squibb. Started Nov 2021; status: completed.
02
Drugs
nivolumab + relatlimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05134948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134948.